Phase 1 study of APX-005M CD40 agonist antibody in children and young adults with CNS tumors

January 13th, 2018|

Principal Institutions: Memorial Sloan Kettering Cancer Center and Pediatric Brain Tumor Consortium (PBTC) – This early phase, multicenter, open-label study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, […]